Dianthus Therapeutics (NASDAQ:DNTH) Issues Earnings Results, Beats Estimates By $0.13 EPS

Dianthus Therapeutics (NASDAQ:DNTH) posted its quarterly earnings results on Wednesday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.13, FiscalAI reports. The firm had revenue of $1.21 million during the quarter, compared to the consensus estimate of $0.46 million. Dianthus Therapeutics had a negative return on equity of 21.15% and a negative net margin of 7,436.50%.

Dianthus Therapeutics Stock Up 3.4%

DNTH stock traded up $2.83 during midday trading on Friday, hitting $85.84. 362,482 shares of the company traded hands, compared to its average volume of 933,966. The business has a 50 day simple moving average of $90.56 and a 200-day simple moving average of $85.38. Dianthus Therapeutics has a twelve month low of $34.29 and a twelve month high of $117.88. The stock has a market capitalization of $4.70 billion, a price-to-earnings ratio of -21.48 and a beta of 1.47.

Analyst Ratings Changes

A number of research analysts have recently issued reports on DNTH shares. Citigroup began coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of Dianthus Therapeutics in a research note on Friday, September 11th. They set an “overweight” rating and a $135.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $158.00 target price on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Wedbush lifted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Buy” and an average target price of $128.77.

Insider Activity

In other news, Director Simon Read sold 2,778 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total transaction of $326,553.90. Following the completion of the transaction, the director directly owned 2,778 shares in the company, valued at $326,553.90. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Edward Carr sold 20,000 shares of the firm’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $101.38, for a total transaction of $2,027,600.00. Following the completion of the sale, the chief accounting officer owned 20,000 shares in the company, valued at $2,027,600. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 72,596 shares of company stock worth $7,748,340. Insiders own 3.02% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.